Journal of Clinical Medicine, 28 February 2020
Tetrahydrocannabinol (THC) is the primary psychoactive ingredient in cannabis. While the safety of THC and cannabis has been extrapolated from millennia of recreational use, medical marijuana programs have increased exposure among medically complex individuals with comorbid co…
Archive for month: February, 2020
Dr. Sherry Yafai is an ER doctor who also integrates cannabis-based medicine in her clinical practice at The Releaf Institute. In this interview with Joe Lemon, she explores the reasons why cannabis- informed healthcare providers are needed more and more.
Dr. Phillip Grob, a geriatric psychiatrist, discusses the potential applications of cannabis for dementia and mental health challenges in the senior population.
Dr. Sherry Yafai of the Releaf Institute discusses the applications of cannabis to reduce or replace the use of opiate drugs. She outlines the opioid epidemic and how cannabis may be used as a tool for harm reduction.
Dr. Cristina Sanchez, a biochemist with over 20 years of experience as a cannabinoid researcher, outlines the preclinical evidence of cannabinoids on different types of cancer.
Dr. Arno Hazekamp discusses the intricacies of the Sativa/Indica debate. He describes metabolic characterists of cannabis constituents and the characteristics of hybrids. Originally recorded at the SCC Quarterly Meeting in March of 2018.
Dr. Kirsten Muller-Vahl, is a physician specializing in neurology and psychiatry, is the world’s authority on cannabis and Tourette’s syndrome. She presents “Tourette Syndrome: Clinical presentation, underlying pathology and treatment options” at the February SCC Quarterly Meeting on January 4, 2018.
Dr. David (Dedi) Meiri presents on “Laboratory of Cancer Biology and Cannabinoid Research” at the SCC Quarterly Meeting on September 17, 2017